Management of prostate cancer patients with lymph node involvement

A rapidly evolving paradigm

Gilles Créhange, Chien Peter Chen, Charles C. Hsu, Norbert Kased, Fergus Coakley, John Kurhanewicz, Mack Roach

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Although widespread PSA screening has inevitably led to increased diagnosis of lower risk prostate cancer, the number of patients with nodal involvement at baseline remains high (nearly 40% of high risk patients initially staged cN0). These rates probably do not reflect the true incidence of prostate cancer with lymph node involvement among patients selected for external beam radiotherapy (EBRT), as patients selected for surgery often have more favorable prognostic features. At many institutions, radical treatment directed only at the prostate is considered standard and patients known to have regional disease are often managed palliatively with androgen deprivation therapy (ADT) for presumed systemic disease. New imaging tools such as MR lymphangiography, choline-based PET imaging or combined SPECT/CT now allow surgeons and radiation oncologists to identify and target nodal metastasis and/or lymph nodes with a high risk of occult involvement. Recent advances in the field of surgery including the advent of extended nodal dissection and sentinel node procedures have suggested that cancer-specific survival might be improved for lymph-node positive patients with a low burden of nodal involvement when managed with aggressive interventions. These new imaging tools can provide radiation oncologists with maps to guide delivery of high dose conformal radiation to a target volume while minimizing radiation toxicity to non-target normal tissue. This review highlights advances in imaging and reports how they may help to define a new paradigm to manage node-positive prostate cancer patients with a curative-intent.

Original languageEnglish (US)
Pages (from-to)956-967
Number of pages12
JournalCancer Treatment Reviews
Volume38
Issue number8
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Lymph Nodes
Radiation
Lymphography
Choline
Androgens
Dissection
Prostate
Radiotherapy
Neoplasm Metastasis
Survival
Incidence
Therapeutics
Neoplasms

Keywords

  • Fluorocholine PET/CT imaging
  • IGRT
  • IMRT
  • Lymph node metastasis
  • MR lymphangiography
  • Prostate cancer
  • Sentinel node
  • SPECT/CT imaging

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Management of prostate cancer patients with lymph node involvement : A rapidly evolving paradigm. / Créhange, Gilles; Chen, Chien Peter; Hsu, Charles C.; Kased, Norbert; Coakley, Fergus; Kurhanewicz, John; Roach, Mack.

In: Cancer Treatment Reviews, Vol. 38, No. 8, 12.2012, p. 956-967.

Research output: Contribution to journalArticle

Créhange, Gilles ; Chen, Chien Peter ; Hsu, Charles C. ; Kased, Norbert ; Coakley, Fergus ; Kurhanewicz, John ; Roach, Mack. / Management of prostate cancer patients with lymph node involvement : A rapidly evolving paradigm. In: Cancer Treatment Reviews. 2012 ; Vol. 38, No. 8. pp. 956-967.
@article{06f00db1b71c46068104742198103ec0,
title = "Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm",
abstract = "Although widespread PSA screening has inevitably led to increased diagnosis of lower risk prostate cancer, the number of patients with nodal involvement at baseline remains high (nearly 40{\%} of high risk patients initially staged cN0). These rates probably do not reflect the true incidence of prostate cancer with lymph node involvement among patients selected for external beam radiotherapy (EBRT), as patients selected for surgery often have more favorable prognostic features. At many institutions, radical treatment directed only at the prostate is considered standard and patients known to have regional disease are often managed palliatively with androgen deprivation therapy (ADT) for presumed systemic disease. New imaging tools such as MR lymphangiography, choline-based PET imaging or combined SPECT/CT now allow surgeons and radiation oncologists to identify and target nodal metastasis and/or lymph nodes with a high risk of occult involvement. Recent advances in the field of surgery including the advent of extended nodal dissection and sentinel node procedures have suggested that cancer-specific survival might be improved for lymph-node positive patients with a low burden of nodal involvement when managed with aggressive interventions. These new imaging tools can provide radiation oncologists with maps to guide delivery of high dose conformal radiation to a target volume while minimizing radiation toxicity to non-target normal tissue. This review highlights advances in imaging and reports how they may help to define a new paradigm to manage node-positive prostate cancer patients with a curative-intent.",
keywords = "Fluorocholine PET/CT imaging, IGRT, IMRT, Lymph node metastasis, MR lymphangiography, Prostate cancer, Sentinel node, SPECT/CT imaging",
author = "Gilles Cr{\'e}hange and Chen, {Chien Peter} and Hsu, {Charles C.} and Norbert Kased and Fergus Coakley and John Kurhanewicz and Mack Roach",
year = "2012",
month = "12",
doi = "10.1016/j.ctrv.2012.05.005",
language = "English (US)",
volume = "38",
pages = "956--967",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Management of prostate cancer patients with lymph node involvement

T2 - A rapidly evolving paradigm

AU - Créhange, Gilles

AU - Chen, Chien Peter

AU - Hsu, Charles C.

AU - Kased, Norbert

AU - Coakley, Fergus

AU - Kurhanewicz, John

AU - Roach, Mack

PY - 2012/12

Y1 - 2012/12

N2 - Although widespread PSA screening has inevitably led to increased diagnosis of lower risk prostate cancer, the number of patients with nodal involvement at baseline remains high (nearly 40% of high risk patients initially staged cN0). These rates probably do not reflect the true incidence of prostate cancer with lymph node involvement among patients selected for external beam radiotherapy (EBRT), as patients selected for surgery often have more favorable prognostic features. At many institutions, radical treatment directed only at the prostate is considered standard and patients known to have regional disease are often managed palliatively with androgen deprivation therapy (ADT) for presumed systemic disease. New imaging tools such as MR lymphangiography, choline-based PET imaging or combined SPECT/CT now allow surgeons and radiation oncologists to identify and target nodal metastasis and/or lymph nodes with a high risk of occult involvement. Recent advances in the field of surgery including the advent of extended nodal dissection and sentinel node procedures have suggested that cancer-specific survival might be improved for lymph-node positive patients with a low burden of nodal involvement when managed with aggressive interventions. These new imaging tools can provide radiation oncologists with maps to guide delivery of high dose conformal radiation to a target volume while minimizing radiation toxicity to non-target normal tissue. This review highlights advances in imaging and reports how they may help to define a new paradigm to manage node-positive prostate cancer patients with a curative-intent.

AB - Although widespread PSA screening has inevitably led to increased diagnosis of lower risk prostate cancer, the number of patients with nodal involvement at baseline remains high (nearly 40% of high risk patients initially staged cN0). These rates probably do not reflect the true incidence of prostate cancer with lymph node involvement among patients selected for external beam radiotherapy (EBRT), as patients selected for surgery often have more favorable prognostic features. At many institutions, radical treatment directed only at the prostate is considered standard and patients known to have regional disease are often managed palliatively with androgen deprivation therapy (ADT) for presumed systemic disease. New imaging tools such as MR lymphangiography, choline-based PET imaging or combined SPECT/CT now allow surgeons and radiation oncologists to identify and target nodal metastasis and/or lymph nodes with a high risk of occult involvement. Recent advances in the field of surgery including the advent of extended nodal dissection and sentinel node procedures have suggested that cancer-specific survival might be improved for lymph-node positive patients with a low burden of nodal involvement when managed with aggressive interventions. These new imaging tools can provide radiation oncologists with maps to guide delivery of high dose conformal radiation to a target volume while minimizing radiation toxicity to non-target normal tissue. This review highlights advances in imaging and reports how they may help to define a new paradigm to manage node-positive prostate cancer patients with a curative-intent.

KW - Fluorocholine PET/CT imaging

KW - IGRT

KW - IMRT

KW - Lymph node metastasis

KW - MR lymphangiography

KW - Prostate cancer

KW - Sentinel node

KW - SPECT/CT imaging

UR - http://www.scopus.com/inward/record.url?scp=84867143264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867143264&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2012.05.005

DO - 10.1016/j.ctrv.2012.05.005

M3 - Article

VL - 38

SP - 956

EP - 967

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 8

ER -